Last reviewed · How we verify
Rapydan
At a glance
| Generic name | Rapydan |
|---|---|
| Also known as | Lidocaine Tetracaine Patch |
| Sponsor | Jazz Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rapydan Topical Anaesthesia for Arterial Cannulation (PHASE4)
- A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel (PHASE4)
- Influence of Rapydan on Clinical Chemistry and Hematology Measurements (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rapydan CI brief — competitive landscape report
- Rapydan updates RSS · CI watch RSS
- Jazz Pharmaceuticals portfolio CI